Doheny Asset Management CA decreased its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 0.5% during the first quarter, Holdings Channel reports. The institutional investor owned 28,150 shares of the biopharmaceutical company’s stock after selling 150 shares during the period. Doheny Asset Management CA’s holdings in FibroGen were worth $694,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the stock. TLP Group LLC acquired a new position in shares of FibroGen during the third quarter valued at about $108,000. Ameritas Investment Partners Inc. acquired a new position in shares of FibroGen during the first quarter valued at about $111,000. Airain ltd acquired a new position in shares of FibroGen during the first quarter valued at about $236,000. SG Americas Securities LLC acquired a new position in shares of FibroGen during the third quarter valued at about $246,000. Finally, Parametric Portfolio Associates LLC acquired a new position in shares of FibroGen during the first quarter valued at about $249,000. 47.74% of the stock is owned by hedge funds and other institutional investors.
FibroGen Inc (NASDAQ:FGEN) traded down 1.83% during trading on Friday, reaching $26.75. 300,400 shares of the company’s stock traded hands. The company has a 50 day moving average price of $26.61 and a 200-day moving average price of $23.85. FibroGen Inc has a 12-month low of $14.50 and a 12-month high of $29.00. The company’s market cap is $1.87 billion.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.11. The firm had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. On average, equities research analysts forecast that FibroGen Inc will post ($1.81) EPS for the current fiscal year.
Separately, Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $37.50.
In related news, CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $27.75, for a total value of $524,475.00. Following the transaction, the chief executive officer now directly owns 3,345,941 shares of the company’s stock, valued at approximately $92,849,862.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Pat Cotroneo sold 6,500 shares of the stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $28.00, for a total transaction of $182,000.00. Following the completion of the transaction, the vice president now directly owns 164,405 shares in the company, valued at $4,603,340. The disclosure for this sale can be found here. Insiders sold a total of 309,016 shares of company stock worth $7,953,185 over the last ninety days. Insiders own 14.90% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.